GLP-1 / GIP / glucagon triple receptor agonist studied in metabolic models.
For research use only. Not for human or veterinary use. No claims of safety, efficacy or therapeutic benefit.
Activation of GLP-1, GIP and glucagon receptors; body-weight and metabolic research. A phase 2 obesity trial reported greater weight reduction than placebo, with gastrointestinal adverse events and heart-rate increases.
Clinical findings apply to the studied formulation, population and indication. They do not establish equivalence, safety or therapeutic efficacy of this research product.
PMID: 37366315
Contact the Avitus team to confirm available presentations, product specifications and pricing for your research requirements.